Highlights from the 20th Scientific Sessions of the American Heart Association: November 12 to 15, 2006, Chicago, Illinois

• Published in: The American heart journal 2007-02, Vol.153 (2), p.213-223
• Main Authors: Mills, James S., MD, Adams, George L., MD, Tricoci, Pierluigi, MD, Melloni, Chiara, MD, Joliceur, E. Marc, MD, MSc, Wang, Tracy W., MD, MS, Thomas, Kevin L., MD
• Format: Article
• Language: English
• Subjects: Cardiology; Cardiomyopathy; Cardiovascular; Clinical trials; Coronary vessels; Cost control; Heart attacks; Heart failure; Hospitalization; Medical imaging; Mortality; Veins & arteries
• ISSN: 0002-8703; 1097-6744
• DOI: 10.1016/j.ahj.2006.12.001

Together with the measured reduction of LV end-systolic volumes, this finding suggests that both high- and low-dose skeletal myoblasts induced positive LV remodeling in ischemic cardiomyopathy. [...]major adverse events, including time to first ventricular arrhythmia, were no different between the groups at 6 months. Early and successful reperfusion therapy with primary percutaneous coronary intervention (PCI) or thrombolysis improves left ventricular systolic function and reduces mortality.1 Despite these advances in therapy for acute myocardial infarction (AMI), approximately one third of eligible patients do not receive early reperfusion therapy.2 Optimal management for patients with persistent total coronary occlusion of the infarct-related artery who are recognized after the accepted period for reperfusion therapy remains variable and controversial.\n Key exclusion criteria were clinical instability, left main or 3-vessel disease, and severe inducible ischemia.